Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises ABGSC in connection with EQL Pharma’s inaugural bond issuance
Mandate

Vinge advises ABGSC in connection with EQL Pharma’s inaugural bond issuance

January 24, 2025 Banking and Finance

Vinge has advised ABG Sundal Collier in connection with EQL Pharma AB (publ)’s ( “EQL”) inaugural issuance of SEK 350,000,000 senior secured bonds within a framework of up to SEK 700,000.

The bonds carry a floating interest rate of STIBOR 3M + 4.00% and have a tenor of three years. EQL intends to apply for admission to trading of the bonds on Nasdaq Transfer Market and the corporate bond list of Nasdaq Stockholm. The net proceeds from the issuance will be used to finance the acquisition of a portfolio with original pharmaceuticals, repayment of existing financial indebtedness and for general corporate purposes.

Vinge’s team consisted of Mikael Ståhl, Arvid Weimers, August Ahlin and Sara Jansson.

Related

Vinge advises Röko AB (publ) in connection with the establishment of its MTN programme

 Vinge has advised Röko AB (publ) ("Röko") on the establishment of a medium-term note programme (the "MTN Programme") with a framework amount of SEK 5 billion.
November 13, 2026

Vinge advises Telavox on the sale of its Nordic customer base to Telia

 Vinge has advised Telavox AB (“Telavox”) on the sale of Telavox’s Nordic customer base for business services to Telia Company AB (“Telia”). The customer base comprises approximately 24,000 business customers and 325,000 end users in Sweden, Denmark, Finland, and Norway. The purchase price amounts to SEK 3.8 billion plus a potential additional earn-out.
November 13, 2026

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026